Skip to content
Cart
Menu

Research

Published findings, in context.

Each finding is shown with the evidence level at which it was observed. A result in an animal model or in cell culture is not a result in humans.

Topic

All topicsTissue damage modelsExtracellular matrixCell signalingCerebral ischemia modelsDermal fibroblasts

Evidence level

All levelsIn vitroAnimalHuman, observationalHuman, controlledReview
More filters (study type, organism, year)

Study type

All typesIn vitro studyAnimal studyObservational (human)Controlled (human)Systematic reviewNarrative reviewCase report
Publication year

3 publications

Human, controlled · Controlled study in humans

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized, double-blind, placebo-controlled 48-week trial in 338 adults: endpoints not summarized in this profile

    The New England Journal of Medicine2023PMID 37366315 (opens PubMed in a new tab)Full record on PubMedDOI 10.1056/NEJMoa2301972 (opens the publisher record in a new tab)

    Filed under GLP-3

    Model
    Randomized, double-blind, placebo-controlled trial of 48 weeks in 338 adults, with several exposure groups and a placebo group; registered as NCT04881760
    Sample size
    338
    Exposure
    Retatrutide, several exposure groups
    Comparator
    Placebo

    Trial funded by the developer, with company employees among the authors, conducted with material supplied by the developer. Its primary and secondary endpoints are not summarized in this profile; they are described in the original record. The authors report that the most common adverse events were gastrointestinal, occurred more often in higher-exposure groups and were mostly mild to moderate, and that heart rate increased with exposure, peaking at 24 weeks and declining thereafter.

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized human trial of finished products with and without GHK-Cu: blinded objective assessments and a self-rated questionnaire

    Miller TR, Wagner JD, Baack BR, et al.Archives of Facial Plastic Surgery2006PMID 16847171 (opens PubMed in a new tab)Title on PubMedDOI 10.1001/archfaci.8.4.252 (opens the publisher record in a new tab)

    Filed under GHK-Cu

    Model
    Randomized trial of finished products with or without GHK-Cu, assessed at 12 weeks by computer-assisted analysis, blinded evaluators and a self-rated questionnaire
    Sample size
    13
    Exposure
    Finished products containing GHK-Cu
    Comparator
    Finished products without GHK-Cu

    Thirteen participants completed the study. Computer-assisted analysis and blinded evaluators found no differences between the groups on the trial's objective measures at 12 weeks; only a self-rated questionnaire showed a difference between the groups (p = 0.04). The trial used finished products, not research material.

  • Human, controlledControlled study in humans· Homo sapiens

    Randomized, evaluator-blinded human trial: a finished tripeptide-copper formulation, an active comparator and an inert vehicle

    Bishop JB, Phillips LG, Mustoe TA, et al.Journal of Vascular Surgery1992PMID 1495150 (opens PubMed in a new tab)Title on PubMedDOI 10.1067/mva.1992.37086 (opens the publisher record in a new tab)

    Filed under GHK-Cu

    Model
    Prospective, randomized, evaluator-blinded trial of three finished formulations
    Sample size
    86
    Exposure
    Finished formulation containing a tripeptide-copper complex
    Comparator
    Active comparator formulation; inert vehicle (placebo)

    Among 86 evaluable participants, the active comparator outperformed both the tripeptide-copper formulation and the inert vehicle on the trial's primary measure, and no advantage of the tripeptide-copper formulation over the vehicle was reported. The trial used a finished formulation, not research material.

For laboratory research use only. Not for human or veterinary use or consumption. Not for diagnostic use. Not evaluated by the U.S. FDA.